Department I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany; Cologne Lymphoma Working Group (CLWG), Cologne, Germany.
Department I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany.
Semin Hematol. 2023 Jul;60(3):157-163. doi: 10.1053/j.seminhematol.2023.06.005. Epub 2023 Jun 28.
Hodgkin lymphoma is a B-cell lymphoma often affecting young adults. Outcomes following intensive chemo- and radiotherapy are generally favourable but leave patients at high risk for early and late toxicities frequently reducing quality of life. Relapsed/refractory disease is regularly difficult to treat and ultimately results in death in a relevant subset of patients. Current strategies for risk stratification and response evaluation rely on clinical features and imaging only, and lack discriminatory power to detect patients at risk for disease progression. Here, we explore how circulating tumor DNA sequencing might help to overcome these shortcomings. We provide an overview over recent technical and methodological developments and suggest potential use cases for different clinical situations. Circulating tumor DNA sequencing offers the potential to significantly augment current risk stratification strategies with the ultimate goal of further individualizing treatment strategies for patients with HL.
霍奇金淋巴瘤是一种 B 细胞淋巴瘤，常影响年轻人。接受强化化疗和放疗后的结果通常较好，但会使患者面临高风险的早期和晚期毒性，经常降低生活质量。复发/难治性疾病通常难以治疗，最终导致部分患者死亡。目前的风险分层和反应评估策略仅依赖于临床特征和影像学，缺乏区分能力来检测有疾病进展风险的患者。在这里，我们探讨了循环肿瘤 DNA 测序如何帮助克服这些缺点。我们提供了最近技术和方法学发展的概述，并为不同的临床情况提出了潜在的应用案例。循环肿瘤 DNA 测序有可能显著增强当前的风险分层策略，最终目标是为 HL 患者进一步个体化治疗策略。
